Etevritamab  (Synonyms: 艾替瑞妥单抗; AMG-596)

Etevritamab (AMG-596) is a bispecific T-cell engager targeting EGFRvIII and CD3. Etevritamab can simultaneously bind to the tumor-specific antigen EGFRvIII on glioblastoma multiforme and CD3 on T cells, thereby activating T-cell proliferation and secretion of cytotoxic substances to induce lysis of the bound tumor cells. Etevritamab can be used for the research of tumors such as glioblastoma multiforme^[1][2].

(scFv-heavy-kappa)-(scFv-heavy-lambda)

Human

CD3E & EGFR

916  [NCBI] & 1956  [NCBI]

P07766 & P00533

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

54.66 kDa

2329692-74-0

液体

Colorless to light yellow

艾替瑞妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  (scFv-heavy-kappa)-(scFv-heavy-lambda)

• [1]. Etevritamab

  [2]. Sternjak A, et al. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII. Mol Cancer Ther. 2021 May;20(5):925-933.  [Content Brief]